Laboratory For Advanced Medicine (LAM) Appoints Chief Regulatory Officer
Liquid biopsy developer Laboratory for Advanced Medicine (LAM) named Jinjie Hu as chief regulatory officer.
You may also be interested in...
While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.
MedRhythms’ digital therapeutics platform aims to improve walking and functional outcomes in patients with multiple sclerosis, Parkinsons’ disease and chronic stroke. With around $32m in funding to date, the start-up boasts collaborations with major medical centers and a partnership with Biogen.
Minute Insight: FundamentalVR Raises $20M In Series B, Further Develop HapticVR For Surgical Training
Fundamental VR, which developed a virtual surgical platform that uses advanced technologies such as haptic (touch) feedback, announced on 11 August it raised $20m in a series B round led by EQT Life Sciences and prior investors Downing Ventures.